6030 Day Break Circle
22 articles about NeuroNascent, Inc.
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
Neuronascent Inc., a privately-held neuron regeneration therapeutics company, announced that the National Institute of Aging, has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investigator.
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
Neuronascent Inc., announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged has been accepted for a poster presentation at the Alzheimer’s Association International Conference to be held in Amsterdam, Holland, on July 19, 2023.
Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer Leahy, Ph.D., MBA, to its Board of Directors.
Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures” has been accepted for a poster presentation at 15th Clinical Trials on Alzheimer’s Disease (CTAD 2022) to be held in San Francisco, Calif., on Nov. 29 through Dec. 2, 2022.
Neuronascent Inc, announced that the U.S. Food and Drug Administration granted “Orphan Drug Designation” for the company’s NNI-351 treatment of Fragile X Syndrome.
Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
Neuronascent Inc. announced that the US Food and Drug Administration granted rare pediatric designation for NNI-351 for Fragile X syndrome.
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease
Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain disorders.
A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons.
Neuronascent Inc., a clinical-stage pharmaceutical company developing first-in-class neuron generating therapeutics, today announced the completion of its Phase 1a trial of NNI-362 for Alzheimer's disease.
Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal
Neuronascent Inc., a privately-held neuron regeneration therapeutics company, announced the publication of results of their novel pharmacotherapy: NNI-362 to allosterically stimulate neural regeneration in human cultures and in vivo models of aging and disease.
Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease
Neuronascent Inc. announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for its proprietary oral therapeutic, NNI-362, to proceed into Phase 1 clinical testing in a healthy aged population.
The claims cover small molecule candidates and the family around these candidates and their human use, adding to the patent coverage in the US and elsewhere.
NeuroNascent, Inc. Announces Expanded Patent Coverage In US And Russia For Its Alzheimer's Disease And Down Syndrome Therapeutics
NeuroNascent, Inc. Successfully Completes Pre-IND Meeting With FDA For Alzheimer's Disease Therapeutic
NeuroNascent, Inc. Announces Issuance Of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate
NeuroNascent, Inc. And ChemDiv, Inc. Announce R&D Collaboration For Development Of A Novel CNS Neurogenic Drug Candidate